Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-1: Orforglipron in Adults With Obesity or Overweight With Weight-Related Comorbidities
2022-502839-19-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Orforglipron with Placebo (2 arms). Primary endpoint: Mean Percent Change from Baseline in Body Weight. Planned start Sep 2023; status: authorised.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2022-502839-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502839-19-00.